期刊
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
卷 44, 期 2, 页码 136-145出版社
WILEY
DOI: 10.1111/eci.12199
关键词
Bioprostheses; Lp-PLA2; structural valve degeneration
资金
- CIHR [MOP114893]
- Quebec Heart and Lung Institute Fund
ObjectivesIn this study, we sought to determine the metabolic markers associated with structural valve degeneration (SVD). BackgroundStructural valve degeneration (SVD) is the major cause of bioprosthetic valve failure leading to bioprostheses (BPs) stenosis or regurgitation. We hypothesized that lipoprotein-associated phospholipase A2 (Lp-PLA2) is involved in the SVD of BPs. MethodsWe included 197 patients who underwent aortic valve replacement with a bioprosthetic valve and had echocardiographic follow-up to evaluate valve function. Moreover, explanted BPs (n=39) were analysed by immunohistochemistry for the expression of Lp-PLA2. ResultsAfter a mean follow-up of 7902years, forty-one patients (21%) were identified as developing SVD. Patients with SVD had significantly higher plasma level of Lp-PLA2 mass (1518 +/- 92ng/mL vs. 1332 +/- 34ng/mL, P=003) and activity (276 +/- 09nmol/min/mL vs. 250 +/- 04nmol/min/mL, P=0005). Multivariate analysis revealed that Lp-PLA2 activity (OR: 109, 95% CI: 101-118; P=003) was the strongest independent predictor of SVD. Immunohistochemistry studies of explanted BP showed that 77% of explanted BPs had the expression of Lp-PLA2, which correlated with the density of macrophages (CD68), and ox-LDL levels in bioprosthetic tissues. ConclusionsIncreased blood plasma activity of Lp-PLA2 is associated with higher prevalence of SVD. These findings open new avenues for the identification of patients at risk for SVD and for the development of pharmacotherapy aiming at the prevention of SVD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据